We are live on ! Find out more

OrthoPediatrics

KIDS

Market cap $875M

33.51 USD

+2.10

6.69%

At close Updated Nov 4, 4:00 PM EST

Pre-market

After hours

33.51

0.00

0%

1 day

6.69%

5 days

9.94%

1 month

46.4%

3 months

60.49%

6 months

112.36%

Year to date

90.83%

1 year

102.11%

5 years

-53.57%

10 years

74.35%

About: OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.

Employees: 602

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 17.6%

Neutral 64.7%

Negative 17.6%

OrthoPediatrics to Participate in Upcoming Conferences

WARSAW, Ind., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in two upcoming investor conferences, held in New York, NY.

OrthoPediatrics to Participate in Upcoming Conferences

Zacks Investment Research

All You Need to Know About OrthoPediatrics (KIDS) Rating Upgrade to Buy

OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About OrthoPediatrics (KIDS) Rating Upgrade to Buy

OrthoPediatrics Corp. (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics Corp. ( KIDS ) Q3 2026 Earnings Call October 27, 2026 4:30 PM EDT Company Participants David Bailey - President, CEO & Director Fred Hite - CFO, Principal Financial & Accounting Officer, COO and Director Conference Call Participants Philip Taylor - Gilmartin Group LLC Caitlin Roberts - Canaccord Genuity Corp., Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Matson - Needham & Company, LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to OrthoPediatrics Corporation's Third Quarter 2026 Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

OrthoPediatrics Corp. (KIDS) Q3 2026 Earnings Call Transcript

The Motley Fool

OrthoPediatrics: 3 Key Takeaways for Long-Term Investors

OrthoPediatrics raised 2026 revenue guidance to $270 million to $273 million. Third-quarter revenue grew 19% year over year to $72.7 million.

OrthoPediatrics: 3 Key Takeaways for Long-Term Investors

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics NASDAQ: KIDS reported record third-quarter revenue and raised its full-year sales outlook, citing broad-based demand across its trauma, deformity, scoliosis and specialty bracing businesses, as well as continued progress from recently introduced products.

OrthoPediatrics Q3 Earnings Call Highlights

Zacks Investment Research

OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.24 per share a year ago.

OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

Record Third Quarter 2026 Revenue of $72.7 Million , Up 19% Year-over-Year

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations

New addition to the Pediatric Nailing Platform expands options for pediatric femoral trauma and deformity correction New addition to the Pediatric Nailing Platform expands options for pediatric femoral trauma and deformity correction

OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

WARSAW, Ind., Oct. 13, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2026 financial results on Tuesday, October 27, 2026 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 27, 2026 at 4:30 p.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

WARSAW, Ind., Oct. 07, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with a new product launch, the OPSB® Knee 'TractorFIX contracture management orthosis.

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

See News Rankings

Price charts implemented using Lightweight Charts™